• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Dow Falls Over 100 Points; Chicago Fed National Activity Index Increases In September

    10/23/23 9:43:01 AM ET
    $AKU
    $INVO
    $LICY
    $LMDX
    Medical Specialities
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $AKU alert in real time by email

    U.S. stocks traded lower this morning, with the Dow Jones index falling over 100 points on Monday.

    Following the market opening Monday, The Dow traded down 0.41% to 32,991.58 while the NASDAQ fell 0.33% to 12,940.56. The S&P 500 also fell, dropping, 0.33% to 4,210.14.

    Check This Out: This Analyst With 85% Accuracy Rate Sees More Than 42% Upside In Amazon.com - Here Are 5 Stock Picks For Last Week From Wall Street's Most Accurate Analysts

     

    Leading and Lagging Sectors

     

    Health care shares fell by just 0.1% on Monday.

    In trading on Monday, energy shares dipped by 1.2%.

     

    Top Headline

     

    The Chicago Fed National Activity Index climbed to +0.02 in September versus a revised reading of -0.22 in the prior month.

     

    Equities Trading UP

     

    LumiraDx Limited (NASDAQ:LMDX) shares shot up 297% to $0.3451 after the company reported a strategic collaboration with AstraZeneca and Everton in the Community to set up England’s first community-based heart and lung screening hub.

    Shares of INVO Bioscience, Inc. (NASDAQ:INVO) got a boost, shooting 209% to $1.67 as the company agreed to acquire NAYA Biosciences in an all-stock transaction.

    Akumin Inc. (NASDAQ:AKU) shares were also up, gaining 90% to $0.2752 after the company reached an agreement with Stonepeak to become a private company.

     

    Equities Trading DOWN

     

    Li-Cycle Holdings Corp. (NYSE:LICY) shares dropped 41% to $1.3499 after the company announced plans to halt construction work on its Rochester Hub project, pending completion of a comprehensive review of the go-forward strategy for the project..

    Shares of Revolution Medicines, Inc. (NASDAQ:RVMD) were down 38% to $17.31 after the company announced it presented clinical activity and safety data from its Phase 1/1b trial of RMC-6236.

    XORTX Therapeutics Inc. (NASDAQ:XRTX) was down, falling 36% to $0.4081 after jumping more than 100% on Friday.

    Also Check This Out: Top 4 Consumer Stocks That May Crash This Quarter

     

    Commodities

     

    In commodity news, oil traded down 0.8% to $87.39 while gold traded down 0.2% at $1,990.30.

    Silver traded down 0.9% to $23.29 on Monday while copper rose 0.3% to $3.5740.

     

    Euro zone

     

    European shares were mostly lower today. The eurozone’s STOXX 600 fell 0.5%, London’s FTSE 100 fell 0.4% while Spain’s IBEX 35 Index fell 0.8% The German DAX fell 0.6% French CAC 40 rose 0.1%, while Italy’s FTSE MIB Index declined 0.1%.

     

    Asia Pacific Markets

     

    Asian markets closed lower on Monday, with Japan’s Nikkei 225 falling 0.83% and China’s Shanghai Composite Index falling 1.47%. India’s S&P BSE Sensex, meanwhile, fell 0.8%.

    Food prices in Singapore rose by 4.3% year-over-year in September following a 4.8% increase in August. Singapore's annual inflation rate rose to 4.1% in September from August's level of 4.0%.

     

    Economics

     

    The Chicago Fed National Activity Index climbed to +0.02 in September versus a revised reading of -0.22 in the prior month.

    Now Read This: $15M Bet On Day One Biopharmaceuticals? Check Out These 3 Stocks Insiders Are Buying

    Get the next $AKU alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AKU
    $INVO
    $LICY
    $LMDX

    CompanyDatePrice TargetRatingAnalyst
    Revolution Medicines Inc.
    $RVMD
    11/18/2025$75.00Outperform
    Wolfe Research
    Revolution Medicines Inc.
    $RVMD
    11/3/2025$77.00Outperform
    RBC Capital Mkts
    Revolution Medicines Inc.
    $RVMD
    10/21/2025$90.00Outperform
    Mizuho
    Revolution Medicines Inc.
    $RVMD
    10/16/2025$85.00Buy
    Stifel
    Revolution Medicines Inc.
    $RVMD
    9/12/2025$72.00Strong Buy
    Raymond James
    Revolution Medicines Inc.
    $RVMD
    9/5/2025$99.00Buy
    Truist
    Revolution Medicines Inc.
    $RVMD
    8/19/2025$75.00Overweight
    Piper Sandler
    Revolution Medicines Inc.
    $RVMD
    8/15/2025$67.00Overweight
    Wells Fargo
    More analyst ratings

    $AKU
    $INVO
    $LICY
    $LMDX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wolfe Research initiated coverage on Revolution Medicines with a new price target

    Wolfe Research initiated coverage of Revolution Medicines with a rating of Outperform and set a new price target of $75.00

    11/18/25 8:26:23 AM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    RBC Capital Mkts initiated coverage on Revolution Medicines with a new price target

    RBC Capital Mkts initiated coverage of Revolution Medicines with a rating of Outperform and set a new price target of $77.00

    11/3/25 9:08:29 AM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Mizuho initiated coverage on Revolution Medicines with a new price target

    Mizuho initiated coverage of Revolution Medicines with a rating of Outperform and set a new price target of $90.00

    10/21/25 7:22:03 AM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AKU
    $INVO
    $LICY
    $LMDX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Schroeder Thilo bought $59,999,962 worth of shares (1,304,347 units at $46.00) (SEC Form 4)

    4 - Revolution Medicines, Inc. (0001628171) (Issuer)

    12/9/24 4:15:16 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Wellings Mark bought $9,031 worth of shares (6,250 units at $1.45), increasing direct ownership by 6% to 110,908 units (SEC Form 4)

    4 - Li-Cycle Holdings Corp. (0001828811) (Issuer)

    9/17/24 4:05:04 PM ET
    $LICY
    Environmental Services
    Industrials

    $AKU
    $INVO
    $LICY
    $LMDX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Goldsmith Mark A exercised 24,010 shares at a strike of $0.54, increasing direct ownership by 10% to 256,479 units (SEC Form 4)

    4 - Revolution Medicines, Inc. (0001628171) (Issuer)

    2/10/26 5:30:31 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    General Counsel Cislini Jeff sold $104,965 worth of shares (908 units at $115.60), decreasing direct ownership by 2% to 46,976 units (SEC Form 4)

    4 - Revolution Medicines, Inc. (0001628171) (Issuer)

    1/23/26 4:31:05 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Operating Officer Horn Margaret A exercised 75,000 shares at a strike of $38.47 and sold $7,542,023 worth of shares (75,000 units at $100.56) (SEC Form 4)

    4 - Revolution Medicines, Inc. (0001628171) (Issuer)

    1/9/26 4:20:44 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AKU
    $INVO
    $LICY
    $LMDX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    XORTX Provides Update on Acquisition of Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems

    CALGARY, Alberta, Feb. 04, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU)), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that further to its press release of October 17, 2025 and an update on December 31, 2025, the Company has entered into an extension agreement with Vectus Biosystems Limited ("Vectus") to allow further time to complete the acquisition of the Renal Anti-Fibrotic Therapeutic Program from Vectus (the "Acquisition"). The term sheet entered into October 17th (the "Term Sheet") to acquire the novel new chemical

    2/4/26 6:00:00 PM ET
    $XRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Revolution Medicines to Participate in Guggenheim Securities Emerging Outlook: Biotech Summit 2026

    REDWOOD CITY, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company's chief executive officer and chairman, will participate in a fireside chat as part of the Guggenheim Securities Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11 at 9:30 a.m. ET. To listen to a live webcast of this event, or access an archived webcast, please visit: https://ir.revmed.com/events-and-presentations. Following the live webcast, a replay will be available on the company's website for at least 14

    2/4/26 4:05:00 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Revolution Medicines Doses First Patient in Clinical Trial Evaluating RMC-5127, a RAS(ON) G12V-Selective Inhibitor

    REDWOOD CITY, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the first patient was dosed in its first-in-human clinical trial evaluating RMC-5127, a RAS(ON) G12V-selective inhibitor. The first-in-human trial, RMC-5127-001 [NCT07349537], is an open-label trial evaluating the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of RMC-5127 as both a monotherapy and in combination settings. The trial will enroll patients with RAS G12V–mutated solid tumors, including pancreatic ductal adenocarcinoma (PDAC), colorectal cancer (CRC),

    1/29/26 8:00:00 AM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AKU
    $INVO
    $LICY
    $LMDX
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Revolution Medicines Inc.

    SCHEDULE 13G/A - Revolution Medicines, Inc. (0001628171) (Subject)

    2/10/26 11:19:49 AM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Revolution Medicines Inc.

    SCHEDULE 13G/A - Revolution Medicines, Inc. (0001628171) (Subject)

    2/9/26 8:53:14 AM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 144 filed by Revolution Medicines Inc.

    144 - Revolution Medicines, Inc. (0001628171) (Subject)

    1/7/26 4:23:03 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AKU
    $INVO
    $LICY
    $LMDX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Li-Cycle Holdings Corp.

    SC 13D/A - Li-Cycle Holdings Corp. (0001828811) (Subject)

    12/9/24 6:03:27 PM ET
    $LICY
    Environmental Services
    Industrials

    Amendment: SEC Form SC 13G/A filed by Revolution Medicines Inc.

    SC 13G/A - Revolution Medicines, Inc. (0001628171) (Subject)

    11/8/24 10:52:39 AM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by Li-Cycle Holdings Corp.

    SC 13D/A - Li-Cycle Holdings Corp. (0001828811) (Subject)

    10/15/24 4:30:29 PM ET
    $LICY
    Environmental Services
    Industrials

    $AKU
    $INVO
    $LICY
    $LMDX
    Financials

    Live finance-specific insights

    View All

    Revolution Medicines Reports Third Quarter 2025 Financial Results and Update on Corporate Progress

    Company is winding down global enrollment for the RASolute 302 clinical trial studying daraxonrasib in patients with previously treated PDAC and remains on track for data readout in 2026Company has initiated RASolute 304, a Phase 3 clinical trial of daraxonrasib as adjuvant treatment for patients with resectable PDAC, and remains on track to initiate RASolute 303 for patients with first line metastatic PDAC this yearDaraxonrasib has received FDA Breakthrough Therapy Designation, Orphan Drug Designation and a Commissioner's National Priority VoucherNew leadership appointments strengthened global development and commercialization capabilitiesRevolution Medicines to hold webcast today at 4:30 p

    11/5/25 4:02:00 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Revolution Medicines to Report Financial Results for Third Quarter 2025 After Market Close on November 5, 2025

    REDWOOD CITY, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the third quarter of 2025 on Wednesday, November 5, 2025, after market close. At 4:30 p.m. ET that day (1:30 p.m. PT), members of Revolution Medicines' senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress. To listen to the live webcast, or access the archived webcast, please visit: https://ir.revmed.com/events-and-presentations. Following the live

    10/29/25 4:05:00 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Revolution Medicines Reports Second Quarter 2025 Financial Results and Update on Corporate Progress

    Strong execution of two ongoing Phase 3 trials of daraxonrasib; for RASolute 302, company is winding down enrollment in U.S. and expects to complete enrollment of the trial this year FDA Breakthrough Therapy Designations granted for two RAS(ON) inhibitors, daraxonrasib and elironrasibCompany entered into $2 billion flexible funding agreement with Royalty Pharma to support bold vision for global development and commercializationRevolution Medicines to hold webcast today at 4:30 p.m. Eastern Time REDWOOD CITY, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicte

    8/6/25 4:02:29 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AKU
    $INVO
    $LICY
    $LMDX
    Leadership Updates

    Live Leadership Updates

    View All

    XORTX Provides Update on Acquisition of Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems

    CALGARY, Alberta, Feb. 04, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU)), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that further to its press release of October 17, 2025 and an update on December 31, 2025, the Company has entered into an extension agreement with Vectus Biosystems Limited ("Vectus") to allow further time to complete the acquisition of the Renal Anti-Fibrotic Therapeutic Program from Vectus (the "Acquisition"). The term sheet entered into October 17th (the "Term Sheet") to acquire the novel new chemical

    2/4/26 6:00:00 PM ET
    $XRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Revolution Medicines Announces Key Leadership Additions, including Alan Sandler, M.D. as Chief Development Officer

    REDWOOD CITY, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the appointment of Alan Sandler, M.D. into the newly created role of chief development officer, as well as the appointment of regional general managers in the U.S. and Europe. "I am delighted to welcome Alan as our chief development officer as we pursue our bold vision to develop new global standards of care for patients with RAS-addicted cancers," said Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines. "As a physician-

    9/29/25 9:00:15 AM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Nano One Announces Resignation of Paul Matysek and Appointment of Industry Veteran Anthony Tse as New Chair of the Board of Directors

    VANCOUVER, BC / ACCESSWIRE / October 1, 2024 / (TSX:NANO)(OTC:NNOMF)(Frankfurt:LBMB)Nano One® Materials Corp. ("Nano One" or the "Company"), a clean technology company with a patented process for the low-cost, low-GHG production of lithium-ion battery cathode active materials (CAM), is pleased to announce that Mr. Anthony Tse has been appointed Chair of the Board of Directors.Mr. Tse will succeed Paul Matysek, who is the founding Chair of Nano One and resigning as part of a planned transition to an advisory role that supports the incoming Chair and Board. Mr. Matysek is honoured to have presided over Nano One's growth and leadership for more than a decade."On behalf of Nano One and our share

    10/1/24 3:05:00 AM ET
    $BEN
    $LICY
    Investment Managers
    Finance
    Environmental Services
    Industrials